DiFUSION Technologies, Inc. is an advanced biomaterials manufacturer located in Georgetown Texas. DiFUSION has developed multiple patent pending MITA Technologies (Metallic Ion Therapeutic Agents) for antimicrobial, cellular repair, tissue regeneration, bone growth, scaffold construction and increased angiogenesis. Our first product CleanFUZE™* was developed as an antimicrobial load-bearing biomaterial for orthopaedic applications and has proven highly successful in animal testing. CleanFUZE™ is currently being scaled up for regulatory submission. DiFUSION is dedicated to leveraging these breakthroughs across multiple healthcare channels – initially targeting the orthopedic market to reduce the rising incidence of Surgical Site Infections (SSIs) in spinal surgeries.
The company was founded and incorporated by Derrick Johns in 2008 as DiFUSION Technologies, Inc. DiFUSION’s Scientific Advisory Board members comprise a team of recognized physicians in the fields of orthopaedics, spinal, biochemical and genetic research. The management team consists of senior-level executives possessing extensive experience in spinal product development and clinical studies. DiFUSION is funded by private investors, having raised $9.2 million since their incorporation – none of which is venture capital or bank funding. They are also able to capture additional funding from the revenue stream provided by their first commercial line, Xiphos™ Posterior Interbody System, launched in October of 2011.